Low-Intensity Electric Fields Applied to Scalp Can Stop, Slow Growth of Tumor Cells in Newly-Diagnosed Glioblastoma
Henry Ford Cancer Institute is one of the few cancer programs in Southeast Michigan fighting the most common and deadly brain cancer with tumor-treatment fields, a low-intensity alternating electric field applied with a wearable device that stops or slows the growth of tumor cells in patients with newly diagnosed glioblastoma (GBM). The FDA-approved Optune® device generates electronic tumor-treating fields – a unique approach that garners hope and debates skepticism. For GBM patient Gill Doyle, the device has become a focal point for optimism.
“We are focusing on the newest, cutting-edge science and bringing the technology along with precision medicine to our patients,” says Tobias Walbert, M.D., director of neuro-oncology at the Henry Ford Cancer Institute. “Our goal is to translate the research we do in clinical trials to patient care in real time.” Henry Ford was part of the initial clinical trial that led to the FDA approval of the device.
Click here to read more.
NeuroSafe 2019 Symposium
Aug. 8-9, 2019; Minneapolis
SNSA Congress 2019
Aug. 8-11, 2019; Cape Town, South Africa
2019 Managing Coding and Reimbursement Challenges
Aug. 22-24, 2019; Rosemont, Ill.
2019 From Cranial to Spine: An Overview of Neurosurgical Topics for the Advanced Practice Provider
Aug. 28-31, 2019; Orlando, Fla.
Sept. 8-11, 2019; Leuven, Belgium